Pathogenesis and detection methods of anti-acetylcholine receptor antibodies in myasthenia gravis
Myasthenia gravis (MG), which affects the endplate region of the postsynaptic neuromuscular junction, is the best-understood autoimmune disease. MG is driven by anti-acetylcholine receptor (AChR) or muscle-specific receptor tyrosine kinase, and 65% of MG patients have anti-AChR-positive generalized...
Saved in:
| Main Author: | Shigeaki Suzuki |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-04-01
|
| Series: | Immunological Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/25785826.2025.2472449 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Myasthenia gravis: The evolving therapeutic landscape
by: Gil I. Wolfe, et al.
Published: (2024-12-01) -
The expectant management of a rare neonatal disease: transient neonatal myasthenia gravis
by: Farin Masra, et al.
Published: (2023-04-01) -
Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation
by: Masaaki Yoshikawa, et al.
Published: (2025-04-01) -
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis
by: Armando Martinez Salazar, et al.
Published: (2025-05-01) -
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
by: Ali A. Habib, et al.
Published: (2025-06-01)